Combining BMS’s expertise in immune-mediated disease and Zenas’s aim to bring innovative immunology-based medicines to patients across the world, the collaboration aims to develop and commercialise obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia.
As part of the agreement, BMS will provide an upfront cash payment of $50m to ZenasZenas, along with additional potential development, regulatory and commercial milestone-based payments, as well as royalties.
BMS is also set to make an additional equity investment in ZenasZenas.
In exchange, BMS will acquire exclusive rights to develop and commercialise obexelimab in the licensed territories.
Obexelimab is an investigational bi-functional, non-cytolytic, humanised monoclonal antibody that binds CD19 and FcyRIIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells.
Commenting on the partnership, Lonnie Moulder, founder and chief executive officer of Zenas, said: "This collaboration marks an important step forward in realising our vision for obexelimab to benefit patients living with autoimmune diseases globally."
"This collaboration represents an important opportunity to address unmet needs for people living with IgG4-RD, for which there are no approved treatment options," said Steve Sugino, senior vice president and general manager at BMS, Japan.
The company looks forward to "[expanding] the reach of obexelimab in the licensed territory and [making] an impact on the lives of patients that are waiting," added Sugino.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.